---

$33.75

-1.7400 ( -4.90% ) 698.5K

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-07-03	Sale	-12000.00	Lyssikatos Joseph P
2024-07-01	Sale	-4250.00	Hohl Benjamin
2024-06-27	Sale	-11422.00	Kintz Samuel
2024-06-20	Sale	-1270.00	Heyman Richard A.